Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

MLA

Ryohei Katayama, et al. “Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-Mutated Non-Small-Cell Lung Cancer.” Nature Communications, vol. 8, no. 1, Mar. 2017, pp. 1–16. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a4f1dd6b5563fa2ad508d337f7273a95&authtype=sso&custid=ns315887.

APA

Ryohei Katayama, Naohiko Inase, Ken Uchibori, Yasushi Okuno, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, & Naoya Fujita. (2017). Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nature Communications, 8(1), 1–16.

Chicago

Ryohei Katayama, Naohiko Inase, Ken Uchibori, Yasushi Okuno, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, and Naoya Fujita. 2017. “Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-Mutated Non-Small-Cell Lung Cancer.” Nature Communications 8 (1): 1–16. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a4f1dd6b5563fa2ad508d337f7273a95&authtype=sso&custid=ns315887.